Abstract 381P
Background
Oral squamous cell carcinoma (OSCC) is highly prevalent in South-East Asia including Indonesia. Recurrence and early mortality in OSCC patients cause significant health burden. Subclassification of patients with high risks of locoregional recurrence and early death is beneficial for planning of treatment intensification and surveillance.
Methods
Formalin-fixed paraffin embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Semi-quantitative German scoring system for p16 was used. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
Results
OSCC recurrences and mortality were observed in in 82% and 78% patients (N=60) after a median follow-up of 32 months. Larger tumor size (T3 and T4) was significantly associated with both recurrences and mortality (OR = 3.967,95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). Positive p16 staining was observed in 31% of tumors. Patients with p16 -positive expression were significantly associated with longer recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months, P=0.048; respectively). Other clinical variables including early stages, negative cervical nodes, non-keratinizing tumors, and negative surgical margin status were significantly associated with longer recurrence-free and survivals (log-rank tests, P<0.05).
Conclusions
P16 -positive staining, early stages, positive cervical lymph node infiltration, and positive surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16 and other clinical markers as prognostic markers in OSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. L. Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract